Development of immunizing agents against dengue;Desarrollo de agentes inmunizantes contra el dengue

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 7, Issue 5, 2000, Pages 286-292

  López Antuñano, Francisco J ^a,b   Mota, Javier ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; GLYCOPROTEIN; DNA VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

DENGUE FEVER; DISEASE CONTROL; IMMUNIZATION;

ARTICLE; DENGUE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; PREVENTIVE HEALTH SERVICE; VIRUS ATTENUATION; DENGUE VIRUS; IMMUNOLOGY; REVIEW;

ANTIGENS, VIRAL; DENGUE; DENGUE VIRUS; HUMANS; VACCINES, DNA; VIRAL VACCINES;

EID: 0034182718     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990;3:376-396.
2. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-496.
3. López Antuñano FJ. Epidemiology and control of malaria and other arthropod borne diseases. Mem Inst Oswaldo Cruz 1992;87(Supl 3):105-114.
4. Shope RE. Concepts of control of Japanese encephalitis and dengue. Southeast Asian J Trop Med Public Health 1997;28(Supl 2):131-134.
5. Lambert PH. Les vaccins de l'an 2000. Bull Soc Pathol Exot 1997;90:238.
6. Hammon WM. Dengue hemorrhagic fever. Do we know its cause? Am J Trop Med Hyg 1973; 22:82-91.
7. Valdés L, Guzmán MG, Kouri G, Delgado J, Carbonell I, Cabrera MV, et al. La epidemiología del dengue y del dengue hemorrágico en Santiago de Cuba, 1997. Rev Panam Salud Pública 1999;6:16-25.
8. Gubler DJ. Resurgent vector-borne diseases as a global health problem. Emerg Infect Dis 1998;4:442-450.
9. Ellis RW. The new generation of recombinant viral subunit vaccines. Curr Opin Biotechnol 1996;7:646-652.
10. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977;146:201-217.
11. Kurane I, Innis BL, Hoke CH Jr, Eckels KH, Meager A, Janus J, et al. T cell activation in vivo by dengue virus infection. J Clin Lab Immunol 1995;46:35-40.
12. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239(4839):476-81.
13. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 1996;98:1684-1691.
14. Staropoli I, Frenkiel MP, Megret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 1997;15:1946-1954.
15. Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J Gen Virol 1997;78:2287-2291.
16. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997;230:300-308.
17. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996;14:329-336.
18. Angsubhakorn S, Yoksan S, Pradermwong A, Nitatpattana N, Sahaphong S, Bhamarapravati N. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis. Southeast Asian J Trop Med Public Health 1994;25:554-559.
19. Gagnon SJ, Zeng W, Kurane I, Ennis FA. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol 1996;70:141-147.
20. Pletnev AG, Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc Natl Acad Sci U S A 1998;95:1746-1751.
21. Chen W, Kawano H, Men R, Clark D, Lai CJ. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 1995;69:5186-5190.
22. Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996;70:4162-4166.
23. Fujita H, Sumiyoshi H, Mori C, Manabe S, Takagi M, Yoshida I, et al. Studies in the development of Japanese encephalitis vaccine: expression of virus envelope glycoprotein V3 (E) gene in yeast. Bull World Health Organ 1987;65:303-308.
24. Sugrue RJ, Fu J, Howe J, Chan Y-C. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J General Virol 1997;78:1861-1866.
25. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996;174:1176-1184.
26. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 1996;55:504-510.
27. Fonseca BA, Pincus S, Shope RE, Paoletti E, Mason PW. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994;12:279-285.
28. Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995;13:1251-1258.
29. Smucny JJ, Kelly EP, MaCarthy PO, King AD. Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein. Am J Trop Med Hyg 1995;53: 432-437.
30. Feighny R, Burrous J, Putnak R. Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. Am J Trop Med Hyg 1994;50:322-328.
31. Green S, Kurane I, Pincus S, Paoletti E, Ennis FA. Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. Virology 1997;234:383-386.
32. Kochel T, Wu S-J, Raviprakash K, Hobart P, Hoffman S, Porter K, et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997;15:547-552.
33. Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 1998;143:997-1003.
34. Cardosa MJ. Dengue vaccine design: issues and challenges. Br Med Bull 1998;54:395-405.
35. Guzmán MG. Avances en el desarrollo de una vacuna contra dengue. Acta Cient Venez 1998;49(Supl 1):38-45.
36. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trend Microbiol 1998;6:23-27.
37. Krieg AM. CpG DNA: a novel immunomodulator. Trend Microbiol 1999;7:64-65.